Tempest Therapeutics, Inc.
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is cu…
Biotechnology
US, South San Francisco [HQ]
Risk Factors
By Management
Not Available
No Risk Factor available yet. You can request "Risk Factors" through an email.